Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a government-owned vaccine factory that exists for one reason: to make Oral Polio Vaccine (OPV) for India’s national immunisation programme. Set up in 1989 under the Department of Biotechnology and running a single plant in Bulandshahr, Uttar Pradesh, it has supplied billions of polio doses to the Government of India since commercial production began in 1996. Everything the company does flows from a single-customer, single-product B2G (business-to-government) model - it fills and finishes imported bulk vaccine into doses and delivers them against supply orders from the Ministry of Health and Family Welfare, which buys almost every vial it produces. # Business segments Two engines at vastly different stages - a polio-vaccine workhorse that is virtually the entire company, and a collection of tiny diversification products that barely register - both dependent on government procurement and grants. ## 1. Oral Polio Vaccine: the company’s reason for being **BIBCOL formulates, fills and supplies bivalent Oral Polio Vaccine almost exclusively to the Ministry of Health and Family Welfare - a single-product, single-customer government supply operation that constitutes nearly one hundred percent of revenue.** - **Built for the national immunisation programme** - the company was established specifically to supply OPV for India’s polio eradication drive, and since inception it has delivered billions of doses to the National Immunisation Programme. Commercial production started in 1996, and in 2016 the plant switched from trivalent to bivalent OPV to match the global polio endgame strategy. - **A finishing plant, not a drug-discovery house** - BIBCOL does not make the active ingredient itself. It perpetually imports bulk vaccine, which is its key input, and then formulates and fills it into finished doses at its WHO-cGMP-compliant facility in Bulandshahr. In FY22, foreign exchange outgo on OPV bulk and VVM (vaccine vial monitor) label imports was roughly ₹85 crore, underlining how much of the value sits with overseas suppliers. - **One buyer sets the terms** - the Ministry of Health and Family Welfare places supply orders, and revenue is recognised only when goods are delivered and ownership passes to the government. The arrangement eliminates credit risk - sales are mostly to the Central Government - but it also means the company has no pricing power and faces the constant threat that the Ministry may stop awarding orders on a nomination basis or withdraw the price preference historically given to public-sector units. - **Energy-hungry production with idle capacity risk** - making one lakh doses of OPV consumed roughly 2.1 million units of electricity and 1.26 lakh litres of light diesel oil in FY22, against a standard of just 4,655 units and 520 litres, suggesting significant process inefficiency or batch-size variability. The plant runs a solar installation with net metering that began in February 2019, but the core manufacturing still depends on purchased grid power and diesel-fired boilers. ## 2. Diversification products: a shelf of tiny bets **A handful of non-polio products - zinc tablets, a diarrhoea management kit, low-calorie sweetener tablets, a hand sanitiser and ready-to-use therapeutic food - exist on paper but generate negligible revenue and show little or no production activity.** - **Pharmaceuticals that barely ship** - the company built a dedicated facility for dispersible zinc tablets with a government capital grant, and it has a pilot plant for a diarrhoea management kit that is still not commissioned. Yet zinc tablet revenue was exactly zero in FY22 and just ₹0.16 lakh in FY21, while the diarrhoea kit has not progressed beyond the project stage. - **Food and consumer items with near-zero traction** - BIB Sweet Tablets (a low-calorie sweetener) and BIB VIT generated either zero or negligible sales in recent years, and the hand sanitiser BIBSANIT brought in just ₹3.52 lakh in FY22 and ₹8.04 lakh in FY21 - rounding errors in the context of the company’s OPV revenues. The standard consumption of electricity and light diesel oil for these products is listed as zero per one lakh doses, confirming that production is effectively dormant. - **Assets that sit idle** - as of March 2020, the zinc tablet segment carried total assets of ₹17.20 lakh against liabilities of ₹25.92 lakh, while the BIB Sweets segment had assets of just ₹0.03 lakh. These figures suggest facilities that are a net drain rather than a meaningful second engine. # Group structure and partners **BIBCOL is a standalone central public-sector enterprise with no subsidiaries, controlled by the Department of Biotechnology through a 59.25% stake held by the President of India, and governed by a board entirely appointed by the administrative ministry.** - **Majority government ownership** - the President of India holds 2.56 crore equity shares out of the total 4.32 crore shares of ₹10 each, giving the Government of India outright control. The company is listed solely on the Bombay Stock Exchange under the symbol ‘Bharat Imuno’. - **No corporate children** - the company has no subsidiaries or associate companies, so its entire fate is tied to the single Bulandshahr plant and its government relationships. - **Ministry-directed governance** - all six or seven directors are appointed or nominated by the Department of Biotechnology, Ministry of Science & Technology, and sitting fees are paid to non-executive directors. The statutory auditors are appointed by the Comptroller and Auditor General of India, reinforcing the public-sector control framework. - **Land leased on nominal terms** - the company has given roughly 14 acres of its land across two locations to the National Institute of Plant Genome Research on a 30-year lease at just ₹10,000 per year, though the lease agreement remains unregistered. - **Tied up with unnamed institutions** - the company says it has partnered with reputed institutions for new product development, but the filings do not name them, leaving the nature and depth of these collaborations unclear.